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ABSTRACT 
Objective: Development and validation of two simple, rapid, accurate and sensitive UV-spectrophotometric methods for simultaneous estimation of 
alogliptin benzoate (ALO) and metformin hydrochloride (MET) in bulk and tablet dosage form. 
Methods: First method (Method A) is simultaneous equation method, which is based on the measurement of absorption at 224 nm and 237 nm for 
both ALO and MET, respectively. Second method (Method B) is an absorption ratio method, which is based on the measurement of absorption at 
251 nm i.e. Iso-absorptive point of ALO and MET and 224 nm which is λmax 
Results: Both the drugs were found to be linear in the concentration range of 0.5-18 µg/ml and correlation co-efficient was found to be 0.9998 and 
0.9992 for ALO and 0.9998 and 1 for MET at 224 nm and 237 nm, respectively for simultaneous equation method. For absorption ratio method, both 
the drugs were found to be linear in the concentration range of 0.5-18 µg/ml and correlation co-efficient was found to be 0.9998 and 0.9997 for ALO 
and 0.9998 and 0.9997 for MET at 224 nm and 251 nm, respectively. Recovery studies at 50, 100 and 150% levels were carried out to assess 
accuracy of the methods. Precision studies were also carried out and %RSD was found to be within the limit (% RSD<2). The percentage assay 
(Method A) was found to be 100.57±1.1367 and 101.24±1.0936 for ALO and MET, respectively. For Method B, percentage assay was found to be 
101.46±0.7160 for ALO and 100.15±0.6953 for MET. 
of ALO. 
Conclusion: The developed methods were found to be simple, rapid, accurate and sensitive. Therefore, both the methods can be successfully 
applied for simultaneous determination of ALO and MET in tablet formulation.  
Keywords: Alogliptin benzoate, Metformin hydrochloride, Simultaneous equation method, Absorption ratio method. 
 
Alogliptin benzoate (ALO) which is chemically 2-({6-[(3R)-3-
aminopiperidin-1-yl]-3-methyl-2, 4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl}methyl) benzonitrile is a dipeptidyl peptidase inhibitor, fig. 
1. ALO slows the inactivation of incretin hormones, thereby 
increasing bloodstream concentrations and reducing fasting and 
postprandial glucose concentrations in a glucose-dependant manner 
in patients with type 2 diabetes mellitus. The inhibition of DPP-4 
increases the amount of active plasma incretins which helps with 
glycemic control [1, 2]. 
Metformin hydrochloride (MET) is 1,1dimethyl biguanidine 
monohydrochloride is a biguanide antidiabetic (fig. 1). It is given 
orally in the treatment of type II diabetes mellitus and is the drug of 
first choice in overweight patients. They do not stimulate insulin 
release but require that some insulin be present in order to exert 
their antidiabetic effect. Possible mechanism of action includes the 
delay in the absorption of glucose from the GIT and increase in 
insulin sensitivity and glucose uptake in to cells and inhibition of 
hepatic gluconeogenesis [3-5].  
 
 
Fig. 1: Chemical structures of ALO (alogliptin benzoate) and 
MET (metformin hydrochloride) 
Literature survey revealed various analytical methods for the 
determination of ALO along with MET and other drugs in their 
pharmaceutical formulation using HPLC [6-10], spectrophotometry 
[11-13] and other techniques. It was observed that most of the 
reported methods did not describe about procurement of tablet 
formulation and remaining methods did not use the tablet 
formulation for assay. All these observations were taken in to 
consideration and it was thought to prepare the tablet formulation 
in laboratory using all the excipients as per the marketed 
formulation. Therefore, the aim of present work is to develop and 
validate simple, rapid, accurate and sensitive simultaneous equation 
and absorption ratio method for the determination of ALO and MET 
in tablet dosage form. The advantages of these proposed methods 
are as follows: both the methods describe the assay procedure 
developed using laboratory made tablet formulation, describes 
standard and sample preparation procedure based on the form of 
analytes under investigation, i.e. alogliptin benzoate (13.60 mg of 
alogliptin benzoate is equivalent to 10 mg of alogliptin). 
ALO was purchased from Swapnroop Drugs and Pharmaceuticals, 
Aurangabad, Maharashtra, India and MET was supplied by Alpha 
Drugs, Vadodara, Gujarat, India. Methanol (AR Grade) was 
purchased from SD Fine Chemicals, Mumbai, India. 
Shimadzu double beam UV-visible spectrophotometer (UV-1800, UV 
Probe, Shimadzu Corporation, Kyoto, Japan) with matched quartz 
cell of 1 cm path length was used for the analysis. All weighing was 
performed on high sensitive Adventurer-Pro, AVG264C electronic 
balance, Ohaus Corporation, Pine Brook, NJ, USA. 
Stock solution of ALO and MET were prepared by weighing 
accurately 13.60 mg of ALO (13.60 mg of alogliptin benzoate is 
equivalent to 10 mg of alogliptin) and 10 mg of MET standard drug 
which was then transferred to a 10 ml volumetric flask separately 
and diluted to 10 ml with methanol to get the concentration of the 
drugs, 1000 µg/ml. From the stock solution 6 µg/ml solutions of ALO 
and MET were prepared and scanned in the range of 200 to 400 nm.  
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ALO and MET tablets (alogliptin benzoate 17 mg equivalent to 12.5 
mg of alogliptin and metformin hydrochloride 500 mg) were 
prepared using all the excipients shown in table 1. 
 
Table 1: Formula of laboratory made tablet formulation 
S. No. Ingredients used Quantity (mg) 
1 Alogliptin benzoate 17 
2 Metformin hydrochloride 500 
4 Microcrystalline cellulose 50 
5 Povidone 20 
6 Crospovidone 12 
7 Magnesium stearate 6 
8 Distilled water q. s. 
Total weight  605 
 
Twenty laboratory made tablets (12.5 mg of ALO and 500 mg of MET) 
were accurately weighed and average weight was calculated. All the 
tablets were crushed to fine powder and the quantity equivalent to 5 
mg of ALO and 200 mg of MET were weighed and transferred to 50 ml 
volumetric flask. Flasks were vortexed after adding 30 ml of methanol 
and shaken for 10 minutes and volume was made up to the mark with 
methanol and filtered through whatman filter paper. From the above 
mentioned solution, 1 ml solution was transferred to 10 ml volumetric 
flask and 3.9 mg equivalents of ALO was also added and the volume 
was made up to the mark with methanol to maintain the same 
concentration for both the drugs. Suitable aliquots were prepared to 
get desired concentrations (ALO 6 µg/ml and MET 6 µg/ml). 
Method A (Simultaneous equation method): After scanning the drug 
solutions between 200 to 400 nm, two wavelengths were selected 
from the overlain spectra of ALO and MET for simultaneous equation 
method. Using the below mentioned simultaneous equation formula, 






A1 ax2− A2 ax1
ax2 ay1− ax1ay2
 
Where, Cx and Cy are the concentrations of ALO and MET, ax1 and ax2 
are absorptivities of ALO at 224 and 237 nm, respectively. ay1 and 
ay2 are absorptivities of MET at 224 nm and 237 nm, respectively. A1 
and A2 are absorbances of mixture at 224 and 237 nm, respectively 
[13]. 
Method B (Absorbance ratio method): In absorbance ratio method, 
ratios of absorption at two selected wavelengths were taken. One is 
at iso-absorptive point and other at λmax 
Where, ax
of one of the component. 
The concentration of two drugs in mixture was calculated by using 















1 and ax2 are the absorptivities of ALO at 224 nm and 251 
nm. ay1 and ay2 
A1 and A2 are the absorbances of mixture at 224 and 251 nm, 
respectively. Cx and Cy are the concentrations of ALO and MET, 
respectively in sample solution [14]. 









Both the developed methods were validated according to ICH 
guidelines. In order to determine the specificity of the method, a 
placebo solution (In-house mixture of all the tablet excipients) was 
prepared and analyzed to evaluate the interference among 
excipients and drugs spectra.  
Linearity and range of the method was checked by analyzing all the 
standard solutions separately, containing both the drugs ALO and 
MET (0.5–18 µg/ml) and absorbances were measured. Calibration 
graphs were plotted using absorbances of standard drug solutions 
versus concentration. Results were subjected to regression analysis 
by the least squares method to calculate the values of slope, 
intercept and correlation coefficient. 
Repeatability was checked by taking two concentrations from the 
linearity range and analyzing repeatedly (n=6). Intra-day and inter-
day precision studies were performed by repeated measurements of 
absorbance of standard solutions three times on the same day and 
three different days. 
Recovery studies were performed by standard addition method. 
Known amount of standard solutions were added to pre-analyzed 
sample solutions at 50, 100 and 150% levels.  
The limit of detection and limit of quantification of ALO and MET 
was calculated using the following equation as per ICH guidelines. 








Where, σ = Standard deviation of the response, S = Slope of the 
calibration curve. 
The robustness of an analytical procedure is refers to its ability to 
remain unaffected by small and deliberate variations in the method 
parameters. The method should be robust enough with respect to all 
critical parameters so as to allow routine laboratory use. Robustness 
of the method was checked on the basis of slight alteration in the 
wave length of detection (±1 nm). 
Stability of the solutions were checked by observing any changes in 
the spectral pattern compared with freshly prepared solutions by 




Fig. 2: Overlain UV–spectra of ALO and MET (6 µg/ml) 
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Sample solution was scanned between 200–400 nm and absorbances 
were measured at 224 and 237 nm for Method A and 224 and 251 nm 
for Method B. Percentage assay was calculated solving simultaneous 
equation for Method A and absorbance ratio for Method B. 
Two simple, sensitive and precise simultaneous equation and 
absorbance ratio methods (Q analysis) were developed and 
validated for the simultaneous estimation of ALO and MET in pure 
and pharmaceutical dosage form. Moreover, the developed 
methods were applied to laboratory made tablet formulation. In 
simultaneous equation method 224 and 237 nm and in absorbance 
ratio method 224 and 251 nm was selected as the wavelength of 
analysis fig. 2. 
The developed method was validated according to ICH guidelines. 
Both the drugs were found to be linear in the concentration range of 
0.5-18 µg/ml. Results were subjected to regression analysis by the 
least squares method to calculate the values of slope, intercept and 
correlation coefficient. Precision studies were also carried out for 
both the methods and % RSD was found to be within the limits 
(%RSD<2), which indicates the developed methods have good 
repeatability and low Inter–day variability. Hence, both the methods 
were found to have good precision (table 2). Recovery studies at 50, 
100 and 150% levels were carried out to assess accuracy of the 
methods (table 3). The results of recovery studies indicate that there 
is no interference from tablet excipients. The values of LOD and LOQ 
were found to be low, which proves the sensitivity of the methods. 
 
Table 2: Summary of validation parameters for proposed methods 
Parameters Drugs Method A Method B 
224 nm 237 nm 224 nm 251 nm 
Beer’s law limit (μg/ml) ALO 0.5-18 µg/ml 
MET 
Correlation coefficient ALO 0.9998 0.9992 0.9998 0.9997 
MET 0.9998 1 0.9998 0.9997 
Slope ALO 0.0779 0.0435 0.0779 0.0204 
MET 0.0399 0.0696 0.0399 0.0204 
Intercept ALO 0.0042 0.0042 0.0042 0.0014 
MET 0.0008 0.0022 0.0008 0.0014 
Intra-day precision (%RSD) (n=3) ALO 1.2603 0.8606 1.2603 1.0874 
MET 0.9860 0.7311 0.9860 1.0874 
Inter-day precision(%RSD) (n=3) ALO 1.4978 1.2548 1.4978 1.6721 
MET 1.5776 1.0381 1.5776 1.6721 
LOD (µg/ml) ALO 0.0695 0.0933 0.0695 0.1412 
MET 0.1095 0.0885 0.1045 0.1412 
LOQ (µg/ml) 
 
ALO 0.2107 0.2826 0.2107 0.4279 
MET 0.3317 0.2682 0.3166 0.4279 
n = Number of determination 
 
Table 3: Recovery study data for ALO and MET by method A and B 
Drug Level (%) Method A Method B 






99.91 1.8062 101.71 0.2033 
100.41 0.4676 101.71 0.6291 






101.13 0.5864 102.13 0.3400 
100.23 0.4503 100.85 1.1122 
100.54 0.6629 96.97 0.9511 
*(n=6), n = Number of determination 
 
Table 4: Analysis of formulation 
Methods Drug Labeled amount (mg/tablet) Amount found (%)* RSD (%)* 
Method A ALO 12.5 100.57±1.1367 1.1303 
MET 500 101.24±1.0936 1.0802 
Method B ALO 12.5 101.46±0.7160 0.7057 
MET 500 100.15±0.6953 0.6942 
*mean±SD (n=6), n = Number of determination 
 
Proposed methods were successfully used for the quantitative 
determination of ALO and MET in tablet formulation. Six replicate 
determinations were carried out and experimental values are 
presented in table 4. The results of percentage assay were found 
to be between 98 and 102. Therefore, the proposed methods can 
be successfully applied for the quantitative analysis of ALO and 
MET in tablet formulation. 
The developed UV-spectrophotometric methods were found to be 
simple, accurate, precise and economical. These methods are also 
found to be more sensitive than the existing methods. Therefore, the 
developed methods can be applied in routine quality control of ALO 
and MET in their tablet dosage form. 
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